Sign in to fuzzto save your conversations, follow your research and come back anytime.
Granules
SectorHealthcare
Granules India Limited is a vertically integrated pharmaceutical company founded in 1991. It manufactures Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). The company specializes in off-patent drugs and first-line defense products like Paracetamol, Ibuprofen, Metformin, and Guaifenesin. Granules India operates seven manufacturing facilities, six in India and one in the US, serving over 300 customers across 80 countries. The company has a strong focus on research and development, with a dedicated R&D center in Hyderabad. Granules India has expanded its operations through acquisitions, capacity enhancements, and the establishment of subsidiaries. It has received various regulatory approvals and certifications for its facilities and products. The company has filed numerous ANDAs, DMFs, and CEPs, and has launched several generic products in the US market.
In the news
Granules India incorporates Brazil subsidiary for pharma expansion
Titan Shares: Motilal Oswal Maintains ₹6,000 Target Amid SKINN Premium Push
5 Stocks to Buy Today: SBI, HAL, Granules India
Granules India Q1 Results: 60% profit surge drives 3% stock jump
Granules India gains 2.14% after securing FTF status for LUMRYZ generic
Granules India rises 1.69% on USFDA EIR with VAI classification
Trading Ideas: Granules, Tata Motors, CG Power & Others on May 21
Top stocks to buy: Granules, UltraTech Cement recommended
Granules India Q4 profit jumps 32% to ₹201.5 cr, stock hits record
Emkay Global recommends Granules India buy with ₹800 target
Granules India unit gets USFDA VAI classification after inspection
Granules India seeks M&A for global expansion beyond US
Granules India's Virginia facility clears USFDA inspection
Granules India Gets Second FDA Approval for ADHD Generics
Company insights, generated from the most recent coverage.
Trading at 32.6x PE after 150%+ rally in 3 years — valuation no longer offers margin of safety for a pharma API/formulations player.
Stock fell 4.24% on Sep 16 after hitting 52-week high of ₹872 — classic 'sell on high' reversal with volume 26% above average, signaling profit booking.
Promoter block deal overhang continues to weigh on sentiment as market digests 17.2 crore shares sold by Dr. Krishna Prasad Chigurupati on Sep 11.